We validated the RNA sequencing results by qPCR and western blotting, which confirmed that flubendazole treatment reduced PCSK9 expression in HCC cells in a dose-dependent manner (Figure S3C and 2E). The gene discussed is PCSK9; the disease is hepatocellular carcinoma.